Compare Smith & Nephew plc (SNN) vs Silvercorp Metals Inc. Common Shares (SVM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Silvercorp Metals Inc. Common Shares — how do they compare? Smith & Nephew plc trades at $27.9 (market cap $11.60B), while Silvercorp Metals Inc. Common Shares trades at $9.53 (market cap $2.21B). The key difference: Smith & Nephew plc is far larger — about 5.2× Silvercorp Metals Inc. Common Shares's market cap, and Smith & Nephew plc pays the higher dividend (2.85%). Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 121 Days and Silvercorp Metals Inc. Common Shares for 0 Days on average.
| SNN | SVM | |
|---|---|---|
Market Cap | $11.60B | $2.21B |
Volume | 971,836 | 1,113,327 |
Sector | Health | Basic Materials |
52-Week High | $37.17 | $15.71 |
52-Week Low | $26.42 | $6.09 |
Typical Hold Time | 121 Days | 0 Days |
Enterprise Value | $14.63B | $1.94B |
Dividend Yield | 2.85% | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $27.88, near its 52-week low, with a mixed technical signal but improving fundamentals. Revenue grew to $6.16B in 2025, with net income margin expanding to 10.08%. Recent product launches like the EVOS PELVIC System and FLOW FLEXTEND COBLATION Wand highlight innovation, though the stock faces bearish moving averages and neutral oscillators.
Outlook is cautious; strong profitability and cash flow support value, but analyst consensus is predominantly Hold amid competitive pressures and recent CFO departure. Risks include execution challenges and debt levels, yet institutional interest from BlackRock's $505M investment signals confidence. The stock offers potential for recovery if operational targets are met.
Silvercorp Metals (SVM) trades at $10.03, down 2.62% on the day, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025 and Q2 2026. Revenue grew significantly from $299M in 2025 to $495M in 2026, though net income margin compressed. Analyst consensus is 60% buy with no sell ratings. Recent news highlights expansion into Ecuador and Kyrgyzstan to diversify geographic risk and a renewed share repurchase program.
The outlook is cautiously optimistic, driven by production expansion and strong operational cash flow, but tempered by execution risks in new jurisdictions and margin pressure. Key opportunities include global growth initiatives and efficient cost structure, while risks involve geopolitical exposure and volatile metal prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Silvercorp Metals Inc. Common Shares
Silvercorp Metals Inc. is a Canadian mining company that operates underground silver-lead-zinc mines and processing plants in China, with additional exploration projects in Ecuador.
Read more on SVM →
